# BMS-5

#### Inhibitor of LIMK1 and LIMK2

BMS-5 is a potent inhibitor of the LIM kinase. It has IC $_{50}$  values of 7nM and 8 nM for LIMK1 and LIMK2 respectively. LIMK1/2 activity was measured via TCA precipitation assay using a biotinylated ADF (actin depolymization factor) as the protein substrate and the kinase domains of LIMK1 and LIMK2 as the enzyme sources in the presence of 1  $\mu$ M ATP.

Kinases, such as LIM kinase 1 (LMK1) and LIM kinase 2 (LMK2), have been identified as participating in signal pathways affecting actin dynamics by deactivating cofilin. Over expression of LIMKI has been found in invasive breast and prostate cancer cell lines and suppression of LIMK 2 expression has been found to limit migration of human fibrosarcoma cells. Thus, the inhibition of LIMKI and/or LIMK2 enzymes have been suggested as targets for treating cancer, including reduction or prevention of metastasis.


## **Ordering Information**

**Order Online** »

ENZ-CHM178-0001	1mg
ENZ-CHM178-0005	5mg

Manuals, SDS & CofA

**View Online** »



### **Handling & Storage**

**Use/Stability** As indicated on product label or CoA when stored as recommended.

Short Term Storage +4°C

Long Term Storage -20°C

**Shipping** Ambient Temperature

#### Regulatory Status RUO - Research Use Only

#### **Product Details**

Alternative Name LIMKi 3, N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-

methylpropanamide

**Appearance** White powder.

CAS 1338247-35-0

Couple Target LIMK

Couple Type Inhibitor

Formula  $C_{17}H_{14}CI_2F_2N_4OS$ 

**Identity** Determined by EM-MS, NMR

**MW** 431.3

Purity ≥98% (HPLC)

**Solubility** Soluble in DMSO (15mM).

